Abstract
Purpose of review: Specific immunotherapy represents the only curative treatment of a specific allergy, and is therefore of great interest in terms of immunological mechanisms and therapeutic developments. Recent findings: Allergen-specific regulatory T cells are induced after the initiation of specific immunotherapy, and are assumed to suppress effector T cells directly mediating allergic inflammation. Therefore regulatory T cells may play a key role in the re-induction of allergen tolerance. Multiple pathways in many systems are described to promote or enhance regulatory T cells. This review summarizes the current view on immunological mechanisms leading to and coming from regulatory T cells. Summary: The highlighted mechanisms may not only contribute to improved specific immunotherapy, but also give insight into a clinically relevant therapy targeting regulatory T cells. The approach of addressing endogenous regulatory mechanisms specifically controlling inflammation instead of targeting inflammation itself is relevant for future pharmacological developments.
Original language | English |
---|---|
Pages (from-to) | 525-530 |
Number of pages | 6 |
Journal | Current Opinion in Allergy and Clinical Immunology |
Volume | 5 |
Issue number | 6 |
DOIs | |
State | Published - Dec 2005 |
Externally published | Yes |
Keywords
- Anergy
- FOXP3
- Suppression
- T
- Tolerance